

Biophytis announces its participation in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR)

Paris, France, Cambridge (Massachusetts, USA), February 25th 2025 – 7:00AM – Biophytis SA (Euronext Growth Paris: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, announces its participation in the *International Conference on Frailty and Sarcopenia Research & Geroscience Task Force (ICFSR)*, taking place from March 12 to 14 in Toulouse.

The *International Conference on Frailty and Sarcopenia Research (ICFSR)* is a leading annual scientific event dedicated to accelerating the development of clinical trials for frail older adults. It brings together researchers, clinicians, and industry professionals to share their experiences and advances in the prevention of frailty, disability, and dependency. All presented research undergoes a rigorous peer-review process by the ICFSR Scientific Committee and are published in the *Journal of Frailty and Aging (JFA)*, a peer-reviewed journal specialized in aging and age-related diseases.

As part of a special session on obesity-associated sarcopenia, Biophytis will present the rationale and preliminary data supporting the clinical development of BIO101 in the preservation of muscle and mobility of patients suffering from obesity treated with GLP-1 receptor agonists.

* * * *

About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start, and Duchenne muscular dystrophy, Phase 1-2 to be started), respiratory diseases (COVID-19, Phase 2-3 completed), and metabolic disorders (obesity, Phase 2 to be started). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company's ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com.

Disclaimer

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based

Press release

on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face" section from the Company's 2023 Financial Report available on BIOPHYTIS website (www.biophytis.com) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

Contacts Biophytis

Relations Investisseurs

Investors@biophytis.com

US Investors

Pascal Nigen – Alpha Bronze

pnigen@alphabronzellc.com

Media contacts

Antoine Denry: antoine.denry@taddeo.fr – +33 6 18 07 83 27

Inès de Mandiargues: ines.demandiargues@taddeo.fr - +33 6 16 16 51 78